Kexing Biopharm Expands Global Collaboration at CPHI Milan

Chinese pharmaceutical company Kexing Biopharm participated in CPHI Milan 2026, held in Milan from October 6-8, 2026. The company presented its global pipeline of innovative drugs, co-developed biosimilars, and a broad portfolio of products commercialized in foreign markets. The event facilitated discussions with international drug purchasers, biotech companies, and industry partners.

In recent years, Kexing Biopharm has established a mature overseas commercialization platform and entered into collaboration agreements with multiple Chinese pharmaceutical companies for over 30 products targeting foreign markets. The company's marketing network spans approximately 70 countries and regions, with nearly 200 registration applications filed abroad. A key product, albumin-bound paclitaxel, has already been commercialized in the EU and UK.

To enhance its European presence, Kexing Biopharm has established a subsidiary in Germany and plans to set up similar entities in France, Spain, Italy, the UK, and the Netherlands. The company's strategic direction, "Innovation + Internationalization," focuses on developing treatments for cancer cachexia, ophthalmic diseases, systemic lupus erythematosus, and inflammatory bowel disease.

With 30 years of experience in industrial-scale biopharmaceutical production, Kexing Biopharm operates mature manufacturing and quality management systems, holding EU-GMP certification for its albumin-bound paclitaxel production line. The company remains committed to innovating and commercializing high-quality medicines, aiming to improve global health through international collaboration.